Figure 7.

Relative effects of the intervention as estimated from the network meta‐analysis model for Psoriasis Area and Severity Index (PASI) 90 and serious adverse events (SAEs)

Drugs are reported in order of primary benefit ranking. Each cell contains the risk ratio (RR) and 95% confidence interval for the two primary outcomes (PASI 90 and SAEs) of the intervention in the respective column versus the class level in the respective row. RRs larger than 1 for the lower triangle and smaller than 1 for the upper triangle favour the treatment on the left. Significant results are highlighted in grey.

ACI: acitretin; ADA: adalimumab; APRE: apremilast; BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; ETA: etanercept; FUM: fumaric acid; IFX: infliximab; ITO: itolizumab; IXE: ixekizumab; GUSEL: guselkumab; MTX: methotrexate; PBO: placebo; PONE: ponesimod; SECU: secukinumab; τ (Tau): estimated heterogeneity standard deviation parameter; TILDRA: tildrakizumab; TOFA: tofacitinib; USK: ustekinumab